Document Detail


Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study.
MedLine Citation:
PMID:  17950833     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The Endeavor zotarolimus-eluting stent (ZES; Medtronic Vascular, Santa Rosa, CA) has been found to provide event-free clinical outcomes to 2 years for the treatment of symptomatic CAD by suppressing neointimal proliferation of the target lesion. The clinical outcomes of patients treated with the Endeavor ZES were evaluated at 4 years after implantation. One hundred consecutive patients with symptomatic ischemic heart disease due to de novo stenotic lesions of native coronary arteries were treated with the Endeavor ZES at 8 centers according to a standardized procedure. At 4 years, 3 patients were lost to follow-up analysis. The incidence of major adverse cardiac events (MACE; defined as death, myocardial infarction, emergent cardiac surgery, or repeat revascularization of the target lesion) was 2% at 4 months, 2% at 1 year, 3% at 2 years, 6.1% at 3 years, and 7.2% at 4 years. The difference in these rates was due to 4 deaths caused by cancer (metastatic melanoma, metastatic adenocarcinoma, small-cell cancer of the bladder, and lung carcinoma). From 2-4 years, there was an additional reported case of target lesion revascularization (TLR). A single case of stent thrombosis occurred at 10 days after the index procedure but no cases occurred thereafter. The treatment of patients with symptomatic CAD due to de novo lesions in native coronary arteries with the Endeavor ZES has sustained clinical benefits to 4 years, with very low rates of MACE and TLR.
Authors:
Ian T Meredith; John Ormiston; Robert Whitbourn; I Patrick Kay; David Muller; Jeffrey J Popma; Donald E Cutlip; Peter J Fitzgerald;
Related Documents :
19001933 - Clinical value of echocardiographic assessment of coronary flow reserve after left ante...
15757603 - A novel mechanism explaining early lumen loss following balloon angioplasty for the tre...
939933 - "torsade de pointes" initiated by electrical ventricular stimulation.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study    
Journal Detail:
Title:  The American journal of cardiology     Volume:  100     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2007 Oct 
Date Detail:
Created Date:  2007-10-22     Completed Date:  2007-12-06     Revised Date:  2008-06-05    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  56M-61M     Citation Subset:  AIM; IM    
Affiliation:
Monash Medical Centre and Monash University, Melbourne, Australia. ian.meredith@myheart.id.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Transluminal, Percutaneous Coronary
Anti-Bacterial Agents / administration & dosage,  therapeutic use*
Coronary Artery Bypass
Coronary Disease / drug therapy*,  therapy
Drug-Eluting Stents*
Female
Follow-Up Studies
Humans
Male
Middle Aged
Sirolimus / administration & dosage,  analogs & derivatives*,  therapeutic use
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/zotarolimus; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographi...
Next Document:  The relation between clinical features, angiographic findings, and the target lesion revascularizati...